Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:CODX NASDAQ:ICU NASDAQ:OSRH NASDAQ:ZYXI On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCODXCo-Diagnostics$3.37$3.33$1.26▼$46.50$12.42M2.745.27 million shs616,187 shsICUSeaStar Medical$3.12$3.80$2.07▼$12.50$12.47M-1.0586,775 shs42,442 shsOSRHOSR$0.39$0.52$0.37▼$1.79$13.75M0.611.02 million shs791,439 shsZYXIZynex$0.13$0.12$0.12▼$2.82$3.80M0.992.32 million shsN/ADon't Wait for the OpenAI IPOThe AI wave will soon hit public markets with Anthropic and OpenAI set to go public later this year. However, you don't have to wait to invest. This report shows seven AI stocks that you can buy today while the big model providers get ready to go public.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCODXCo-Diagnostics0.00%-21.45%-9.16%+30.12%-59.82%ICUSeaStar Medical0.00%+4.70%-21.21%+39.91%-68.16%OSRHOSR0.00%+2.83%-23.19%-10.34%-75.81%ZYXIZynex0.00%0.00%0.00%0.00%-94.81%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCODXCo-Diagnostics$3.37$3.33$1.26▼$46.50$12.42M2.745.27 million shs616,187 shsICUSeaStar Medical$3.12$3.80$2.07▼$12.50$12.47M-1.0586,775 shs42,442 shsOSRHOSR$0.39$0.52$0.37▼$1.79$13.75M0.611.02 million shs791,439 shsZYXIZynex$0.13$0.12$0.12▼$2.82$3.80M0.992.32 million shsN/ADon't Wait for the OpenAI IPOThe AI wave will soon hit public markets with Anthropic and OpenAI set to go public later this year. However, you don't have to wait to invest. This report shows seven AI stocks that you can buy today while the big model providers get ready to go public.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCODXCo-Diagnostics0.00%-21.45%-9.16%+30.12%-59.82%ICUSeaStar Medical0.00%+4.70%-21.21%+39.91%-68.16%OSRHOSR0.00%+2.83%-23.19%-10.34%-75.81%ZYXIZynex0.00%0.00%0.00%0.00%-94.81%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCODXCo-Diagnostics 2.00Hold$67.501,902.97% UpsideICUSeaStar Medical 2.00Hold$8.00156.41% UpsideOSRHOSR 1.00SellN/AN/AZYXIZynex 2.00Hold$4.903,820.00% UpsideCurrent Analyst Ratings BreakdownLatest ZYXI, CODX, OSRH, and ICU Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/11/2026CODXCo-Diagnostics Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeSell (D-) ➝ Sell (E+)5/26/2026CODXCo-Diagnostics Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeSell (E+) ➝ Sell (D-)5/14/2026ICUSeaStar Medical Maxim GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingSet Price TargetBuy$6.00 ➝ $8.004/21/2026ICUSeaStar Medical Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)3/27/2026OSRHOSR Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)(Data available from 6/21/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCODXCo-Diagnostics$620K20.06N/AN/A$9.14 per share0.37ICUSeaStar Medical$1.23M10.15N/AN/A$2.75 per share1.13OSRHOSR$2.91M4.73N/AN/A$4.95 per share0.08ZYXIZynex$108.20M0.04$0.25 per share0.51$1.12 per share0.11Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCODXCo-Diagnostics-$46.90M-$15.77N/AN/AN/A-6,760.63%-164.92%-141.15%8/14/2026 (Estimated)ICUSeaStar Medical-$12.15M-$4.80N/AN/AN/A-828.62%-146.29%-96.48%8/12/2026 (Estimated)OSRHOSR-$27.06M-$0.33N/AN/AN/A-363.26%-7.24%-5.41%N/AZYXIZynex$2.99M-$2.43N/A0.27N/A-68.35%-804.30%-36.67%N/ALatest ZYXI, CODX, OSRH, and ICU EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/14/2026Q1 2026CODXCo-Diagnostics-$3.75-$4.06-$0.31-$4.06$0.13 million$0.15 million5/13/2026Q1 2026ICUSeaStar Medical-$0.8250-$0.90-$0.0750-$0.90$0.44 million$0.50 million5/13/2026Q1 2026OSRHOSRN/A-$0.09N/A-$0.0880N/A$0.48 million3/31/2026Q4 2025CODXCo-Diagnostics-$3.90-$16.65-$12.75-$16.65$0.13 million$0.26 million3/25/2026Q4 2025ICUSeaStar Medical-$0.97-$0.80+$0.17-$0.80$0.22 million$0.42 millionCompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthCODXCo-DiagnosticsN/AN/AN/AN/AN/AICUSeaStar MedicalN/AN/AN/AN/AN/AOSRHOSRN/AN/AN/AN/AN/AZYXIZynexN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCODXCo-DiagnosticsN/A2.282.09ICUSeaStar MedicalN/A2.732.71OSRHOSRN/A0.160.14ZYXIZynex0.560.470.32Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCODXCo-Diagnostics14.99%ICUSeaStar Medical1.69%OSRHOSR55.30%ZYXIZynex29.68%Insider OwnershipCompanyInsider OwnershipCODXCo-Diagnostics5.40%ICUSeaStar Medical0.70%OSRHOSR36.80%ZYXIZynex49.28%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableCODXCo-Diagnostics1003.69 million3.49 millionOptionableICUSeaStar Medical24.00 million3.97 millionNot OptionableOSRHOSRN/A35.10 million22.19 millionN/AZYXIZynex77030.39 million15.41 millionOptionableZYXI, CODX, OSRH, and ICU HeadlinesRecent News About These CompaniesZYXIQ CLASS ACTION DEADLINE TONIGHT: Faruqi & Faruqi, LLP Reminds Zynex (ZYXIQ) Investors of Securities Class Action Deadline on April 21, 2026April 21, 2026 | newsfilecorp.comNZYXIQ INVESTOR ALERT Bernstein Liebhard LLP Announces A Securities Fraud Class Action Lawsuit Has Been Filed Against Zynex, Inc.April 16, 2026 | globenewswire.comZYNEX LEAD PLAINTIFF DEADLINE APPROACHING: Bragar Eagel & Squire, P.C. Reminds Zynex, Inc Investors to Contact the Firm Before the April 21st Lead Plaintiff DeadlineApril 13, 2026 | globenewswire.comLevi & Korsinsky Notifies Zynex, Inc. Investors of a Class Action Lawsuit and Upcoming Deadline – ZYXIQApril 13, 2026 | globenewswire.comGainey McKenna & Egleston Announces A Class Action Lawsuit Has Been Filed Against Zynex, Inc. (ZYXIQ)April 10, 2026 | globenewswire.comZYXIQ Shareholder Alert: April 21, 2026 Lead Plaintiff Deadline in Zynex, Inc. Securities Class Action Lawsuit — The Gross Law FirmApril 10, 2026 | globenewswire.comZYXIQ EQUITY ALERT: Faruqi & Faruqi, LLP Reminds Zynex (ZYXIQ) Investors of Securities Class Action Deadline on April 21, 2026April 9, 2026 | newsfilecorp.comNZYXIQ INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Reminds Zynex Investors of Securities Class Action Deadline on April 21, 2026April 3, 2026 | prnewswire.comZYXIQ UPCOMING DEADLINE: Faruqi & Faruqi, LLP Reminds Zynex (ZYXIQ) Investors of Securities Class Action Deadline on April 21, 2026April 1, 2026 | globenewswire.comZynex, Inc. Sued for Securities Law Violations - Contact Levi & Korsinsky Before April 21, 2026 to Discuss Your Rights - ZYXIQApril 1, 2026 | prnewswire.comZYXI SHAREHOLDER ALERT: Hagens Berman Alerts Zynex (ZYXI / ZYXIQ) Investors to Securities Class Action Following Bankruptcy and Federal Fraud SettlementsMarch 30, 2026 | prnewswire.comZYXIQ Shareholder Alert: Investors With Losses May Seek to Lead the Class Action in Zynex, Inc. Securities Lawsuit — The Gross Law FirmMarch 27, 2026 | globenewswire.comZYXI SHAREHOLDER UPDATE: Hagens Berman Alerts Zynex (ZYXI / ZYXIQ) Investors to Securities Class Action Following Bankruptcy and Federal Fraud SettlementsMarch 24, 2026 | prnewswire.comZYXIQ CLASS ACTION NOTICE: Faruqi & Faruqi, LLP Reminds Zynex (ZYXIQ) Investors of Securities Class Action Deadline on April 21, 2026March 23, 2026 | newsfilecorp.comNZYXI ALERT: Hagens Berman Alerts Zynex (ZYXI / ZYXIQ) Investors to Securities Class Action Following Bankruptcy and Federal Fraud SettlementsMarch 20, 2026 | prnewswire.comZYXI SHAREHOLDER NOTICE: Hagens Berman Alerts Zynex (ZYXI / ZYXIQ) Investors to Securities Class Action Following Bankruptcy and Federal Fraud SettlementsMarch 19, 2026 | globenewswire.comShareholders that lost money on Zynex, Inc. (ZYXIQ) Urged to Join Class Action - Contact Levi & Korsinsky to Learn MoreMarch 18, 2026 | prnewswire.comZYXI INVESTOR ALERT: Hagens Berman Alerts Zynex (ZYXI / ZYXIQ) Investors to Securities Class Action Following Bankruptcy and Federal Fraud SettlementsMarch 17, 2026 | globenewswire.comZYXIQ UPCOMING DEADLINE: Faruqi & Faruqi, LLP Reminds Zynex Investors of Securities Class Action Deadline on April 21, 2026March 14, 2026 | newsfilecorp.comNHagens Berman Alerts Zynex (ZYXI / ZYXIQ) Investors to Securities Class Action Following ...March 13, 2026 | bakersfield.comBNew MarketBeat Followers Over TimeMedia Sentiment Over Time Top HeadlinesView All HeadlinesSpaceX Gets the Attention, But These 4 Stocks Could Get the ReturnsBy Bridget Bennett | May 25, 20265 Stocks Winning the AI Race While Everyone Watches NVIDIABy Bridget Bennett | May 26, 2026The Smart Glasses Gold Rush Is Leaving Old-School Eyewear BehindBy Jeffrey Neal Johnson | May 24, 20265 Under-the-Radar AI Stocks to Watch in JuneBy Thomas Hughes | May 31, 2026Is Co-Diagnostics National Security’s Next Diagnostic Pick?By Jeffrey Neal Johnson | May 28, 2026ZYXI, CODX, OSRH, and ICU Company DescriptionsCo-Diagnostics NASDAQ:CODX$3.37 0.00 (0.00%) Closing price 06/18/2026 04:00 PM EasternExtended Trading$3.44 +0.06 (+1.93%) As of 06/18/2026 07:56 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Co-Diagnostics, Inc., a molecular diagnostics company, develops, manufactures, and sells reagents used for diagnostic tests that function through the detection and/or analysis of nucleic acid molecules in the United States and internationally. The company offers Co-Dx PCR platform, a polymerase chain reaction (PCR) testing to patients in point-of-care and at-home setting. It also provides PCR diagnostic tests for COVID-19, influenza, tuberculosis, hepatitis B and C, human papillomavirus, malaria, chikungunya, dengue, and the zika virus. In addition, the company offers three multiplexed tests to test mosquitos for the identification of diseases carried by the mosquitos; molecular tools for detection of infectious diseases, liquid biopsy for cancer screening, and agricultural applications; tests that identify genetic traits in plant and animal genomes; and portable diagnostic device designed to bring PCR to patients in point-of-care and at-home settings. The company was incorporated in 2013 and is headquartered in Salt Lake City, Utah.SeaStar Medical NASDAQ:ICU$3.12 0.00 (0.00%) Closing price 06/18/2026 04:00 PM EasternExtended Trading$3.11 -0.01 (-0.32%) As of 06/18/2026 07:21 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.SeaStar Medical Holding Corporation, a medical device company, develops a platform therapy to reduce the consequences of hyperinflammation on vital organs in the United States. The company offers inflammatory response to fend off infections and repair damaged tissue in the body. It is also developing products in various therapeutic areas, including pediatric and adult acute kidney injury on CRRT; cardiorenal syndrome in congestive heart failure; myocardial stunning in end stage renal disease; and hepatorenal syndrome. The company is headquartered in Denver, Colorado.OSR NASDAQ:OSRH$0.39 0.00 (0.00%) Closing price 06/18/2026 04:00 PM EasternExtended Trading$0.38 -0.01 (-1.99%) As of 06/18/2026 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.OSR Holdings leverages its international network of partners in the US, Europe, and South Korea to market and license its pipeline of proprietary platform technologies for broad application to efficient clinical trial programs, with the ultimate goal of addressing unmet medical needs. We partner with biotherapeutics companies with innovative and proprietary drug R&D "platform technologies" versus "assets only" companies, whose commercial viability is heavily dependent on positive results for individual treatment modalities in extremely rigorous and time consuming clinical trials. We focus on value creation through investments and collaborations with US and EU biotech companies, with the strategic goal of expansion into South Korea (specifically) and Asia (generally). OSR Holdings is headquartered in Paju, South Korea.Zynex NASDAQ:ZYXI$0.12 0.00 (0.00%) As of 06/18/2026Zynex, Inc., together with its subsidiaries, designs, manufactures, and markets medical devices to treat chronic and acute pain; and activate and exercise muscles for rehabilitative purposes with electrical stimulation. The company offers NexWave, a dual channel, multi-modality interferential current, transcutaneous electrical nerve stimulation, and neuromuscular electrical stimulation (NMES) device that is marketed to physicians and therapists by field sales representatives; NeuroMove, an electromyography and electric stimulation technology device; InWave, an electrical stimulation product for the treatment of female urinary incontinence; E-Wave, an NMES device; M-Wave, an NMES device. It also supplies private labeled products, including electrodes for the delivery of electrical current to the body, and batteries for use in electrotherapy products. In addition, the company distributes Comfortrac/Saunders for cervical traction, JetStream for hot/cold therapy, LSO Back Braces for lumbar support, and braces for rehabilitation support. Further, it offers Zynex Fluid Monitoring System (CM-1500); Zynex Wireless Fluid Monitoring System (CM-1600), a noninvasive monitoring device designed to measure relative changes in fluid volume in adult patients; NiCO CO-Oximeter, a laser-based noninvasive co-oximeter; and HemeOx tHb Oximeter, a laser-based total hemoglobin pulse oximeter. The company provides its products for use in pain management and control; stroke and spinal cord injury rehabilitation; hemodynamic monitoring and intravascular volume monitoring; and pulse oximetry monitoring. It sells its products through direct sales force primarily in the United States. Zynex, Inc. was founded in 1996 and is headquartered in Englewood, Colorado. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 06/15 - 06/19 Applied Materials Stock Looks Pricey—Can AI Demand Justify the Rally? Satellogic Is Tiny But Its Revenue Growth Is Hard to Ignore Aehr Spikes on New Order, But Has Stock Gotten Ahead of Itself? Why Kroger’s Pullback Could Be a Gift for Patient Investors Credo Technologies Accelerates AI—Its Stock Price Will Follow Why Rocket Lab’s Nasdaq-100 Moment Could Change the Story Why Palantir’s Google Cloud Deal Could Change the Debate Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
